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Foundation, Cleveland, Ohio.BACKGROUND Data from randomized trials have suggested a
modest or no effect of conventional cardiac resynchronization ther-
apy (convCRT) on the incidence of atrial ﬁbrillation (AF). AdaptivCRT
(aCRT, Medtronic, Mounds View, MN) is a recently described algorithm
for synchronized left ventricular (LV) pacing and continuous optimi-
zation of cardiac resynchronization therapy (CRT).
OBJECTIVE We compared the long-term effects of aCRT with
convCRT pacing on the incidence of AF.
METHODS The Adaptive CRT trial randomized CRT-deﬁbrillator (CRT-
D)–indicated patients (2:1) to receive either aCRT or convCRT pacing.
The aCRT algorithm evaluates intrinsic conduction every minute,
providingLV-onlypacingduringnormal atrioventricular (AV)conduction
and AV and ventriculoventricular timing adjustments during prolonged
AV conduction. The primary outcome of this subanalysis was an episode
of AF.48 consecutive hours as detected by device diagnostics.
RESULTS Over a follow-up period with a mean and standard devi-
ation of 20.2 6 5.9 months, 8.7% of patients with aCRT and
16.2% with convCRT experienced the primary outcome (hazard
ratio [HR] 5 0.54; 95% conﬁdence interval [CI] 5 0.31–0.93;Clinical Trial Registration: http://clinicaltrials.gov/ct2/show/NCT0098
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licenses/by-nc-nd/4.0/).P 5 .03). In patients with prolonged baseline AV, the incidence
of the primary outcome was 12.8% in patients randomized to
aCRT compared with 27.4% in convCRT patients (HR 5 0.45;
95% CI 5 0.24–0.85; P 5 .01). Also, patients with AF episodes
adjudicated as clinical adverse events were less common with
aCRT (4.3%) than with convCRT (12.7%) (HR 5 0.39; 95% CI 5
0.19–0.79; P 5 .01).
CONCLUSION Patients receiving aCRT had a reduced risk of AF
compared with those receiving convCRT. Most of the reduction in
AF occurred in subgroups with prolonged AV conduction at baseline
and with signiﬁcant left atrial reverse remodeling.
KEYWORDS Atrial ﬁbrillation; AV conduction; Cardiac resynchroni-
zation therapy; Clinical outcome; Heart failure; LV pacing
(Heart Rhythm 2017;14:1820–1825) © 2017 The Authors. Pub-
lished by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atrial ﬁbrillation (AF) is a common comorbidity among heart
failure (HF) patients and is associated with an increased risk
of hospitalization, stroke, and death.1–4 The prevalence of AF
reported in recent HF studies and registries ranges from 10%
to 15% in mild-to-moderate chronic HF and up to approxi-
mately 50% in patients with severe HF.5–7 According to
the Framingham Heart study, 20% of HF patients develop
AF within 4 years.5
In numerous trials, cardiac resynchronization therapy
(CRT) consistently improved quality of life, reduced HF hos-
pitalizations, and reduced risk of death.8–10 However, the
ythm Society.
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have suggested that CRT reduces the risk of AF.11–16 Yet, data
from 3 large clinical trials have shown conﬂicting results; 1
study found no beneﬁt,17 another found beneﬁt only in pa-
tients with signiﬁcant left atrial (LA) remodeling,18 and a third
found a trend toward an increased incidence of AF.19
The AdaptivCRT algorithm (aCRT, Medtronic, Mounds
View, MN) was designed to continually adjust CRT to the pa-
tient’s intrinsic atrioventricular (AV) conduction. The algo-
rithm adjusts AV and interventricular pacing intervals and
withholds right ventricular (RV) pacing when normal AV con-
duction exists—fusing the left ventricular (LV) stimulation to
intrinsic conduction. During periods of prolonged AV conduc-
tion, the algorithm continuously optimizes AV and ventriculo-
ventricular (VV) intervals. The algorithm is noninferior to
conventional CRT (convCRT) pacing and may increase
responder rates and improve clinical outcomes.20–22
RV pacing has been shown to increase the risk of AF in
patients with sinus node dysfunction.23–25 As aCRT
signiﬁcantly reduces RV pacing, we hypothesized that the
incidence of AF would be reduced with the algorithm. This
study examines the long-term effects of aCRT on the inci-
dence of AF using data from the Adaptive CRT trial.Methods
The aCRT algorithm
The aCRT algorithm aims to provide fusion pacing by eval-
uating intrinsic conduction every minute. During normal AV
conduction (200 ms), synchronized LV-only pacing is pro-
vided by preempting the atrial to RV sense interval by 40
ms. During prolonged AV conduction (.200 ms), aCRT
pacing is provided with adjustment to the AV and VV timing
based on intervals of atrial to RV sense, atrial to P-wave end,
and RV sense to QRS end.26,27
The Adaptive CRT trial
The trial design and primary results of the Adaptive CRT trial
have been previously published, and the protocol was
approved by the ethics committee at each participating insti-
tution and associated national and local regulatory
agencies.22,26 The Adaptive CRT was a noninferiority
study to test the performance of aCRT vs convCRT.
Patients implanted with CRT with deﬁbrillation therapy
(CRT-D) for clinical indications of New York Heart
Association functional class III or IV HF symptoms, LV
ejection fraction 35%, and QRS duration 120 ms were
randomized in a 2:1 ratio to receive aCRT or echo-
optimized convCRT pacing. Patients and clinicians were
both blinded to the assigned treatment. Primary objectives
were met, demonstrating the algorithm’s safety and effective-
ness of improving the patient clinical composite mean score
by 6 months at a rate similar to that of the control arm.
AF substudy
Atrial arrhythmia information was extracted from the device
diagnostics report for all patients at each study visit. Contin-uous data were available from randomization through to the
end of the follow-up period. As a post hoc analysis, the pri-
mary outcome was deﬁned as time to 2 consecutive days
of 23 hours of device-detected AF (ie, .48 consecutive
hours of AF). This outcome was chosen because of its rela-
tionship with thromboembolic risk.28Additional outcomes and analyses
To explore the relationship between the 2 components of the
aCRT algorithm, we examined the incidence of the primary
end point in subgroups of patients with normal AV conduc-
tion and prolonged AV conduction at randomization. In pa-
tients with normal baseline AV conduction (deﬁned as
intrinsic AV 200 ms when in sinus rhythm or AV 250
ms when receiving atrial pacing), the expectation is that
much of the time they will receive synchronized LV pacing.
In patients with prolonged AV conduction, the expectation is
that most of the time the patient will receive biventricular
pacing with optimized AV and VV intervals.
In addition to the primary end point of 48 hours of AF, the
time to the ﬁrst occurrence of other shorter and longer dura-
tions of AF was analyzed. Also, we examined the incidence
of the primary end point in a number of additional subgroups.
In addition, the incidence of AF episodes that met the proto-
col deﬁnition of new or worsening adverse event, including
all deaths and all hospitalizations, were compared. Such
adverse events were collected prospectively and deﬁned as
any untoward medical occurrence in a participant. All
adverse events were reviewed and adjudicated by a blinded
independent committee for relatedness and severity. We
also examined incidence of persistent AF (deﬁned as contin-
uous episode .7 days). Finally, we assessed baseline and
change (after 6 months) in LA area by 2-dimensional echo-
cardiography measured by a blinded core laboratory at the
University of Pittsburgh. For this latter analysis patients
were classiﬁed as LA responders (LA area decreased
.20% between baseline and 6 months) or LA nonresponders
(LA area decreased,20% or increased between baseline and
6 months).18Statistical analysis
Continuous variables are reported as mean plus or minus
standard deviation (SD). Cumulative incidence curves are
based on the Kaplan–Meier method, with time 0 being the
date of randomization unless otherwise speciﬁed. Com-
parisons are made using the log-rank test. Cox propor-
tional hazard methods are used to compare subgroups,
with the P value of the interaction between randomization
and the subgroup reported. Adverse event rates were
compared using Kaplan–Meier methods and the log-
rank test. A multivariable Cox proportional hazards
model was used to examine whether aCRT was still sig-
niﬁcant after adjusting for other variables. Variables
known or suspected to affect AF were chosen for the
model. Because these variables affect AF, the full model
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Figure 1 Incidence of primary end point (48 consecutive hours of atrial
ﬁbrillation).Results
Patients and follow-up
The baseline characteristics of the patients (N 5 478) are
shown in Table 1. Two patients with permanent AF were
excluded from this analysis. Also, 18% had a history of AF
but were in sinus rhythm at randomization and thus were
included in analysis. Patients were followed for an average
of 20.2 6 5.9 months. Total ventricular pacing (95.0% 6
8.5%) was similar between groups; however, LV-only pacing
was used 35.3% 6 37.1% of the time in the aCRT patients,
whereas convCRT patients were always paced biventricu-
larly when ventricular paced.Primary outcome
During the follow-up period, 8.7% of patients with aCRT and
16.2% of patients with convCRT experienced the primary
outcome of an AF event of .48 hours, which was a 46%
reduced risk with aCRT (hazard ratio [HR]5 0.54; 95% con-
ﬁdence interval [CI] 5 0.31–0.93; P 5 .03) compared with
convCRT patients (Figure 1). The multivariable analysis
(Table 2) demonstrated that aCRT had a signiﬁcant indepen-
dent effect (HR 5 0.51; 95% CI 5 0.29–0.91; P 5 .02) on
the primary outcome even after adjusting for variables that
affect the incidence of AF.Incidence of AF stratiﬁed by baseline AV
conduction
The incidence of AF was stratiﬁed by baseline AV conduction
interval. In patients with normal baseline AV conduction,Table 1 Baseline demographics
Patient characteristic
Adaptive CRT
(n 5 318)
Conventional CRT
(n 5 160)
Age, y, mean 6 SD 65.4 6 11.2 66.2 6 9.7
Male, % 69 68
NYHA class III, % 94 96
LVEF, %, mean 6 SD 24.7 6 6.6 24.9 6 6.5
QRS, ms, mean 6 SD 154.3 6 20.9 155.7 6 21.4
LBBB, % 75 80
AV block: ﬁrst, second,
third degree, %
25, 2, 4 23, 3, 3
Ischemic, % 45 51
Beta-blockers, % 91 91
ACE-i/ARB, % 86 89
History of AF, % 18 19
Antiarrhythmic drug, % 17 16
Oral anticoagulation, % 19 23
Left atrial area, cm2,
mean 6 SD
22.8 6 6.4 23.3 6 6.6
ACE-i/ARB 5 angiotensin converting enzyme inhibitor/angiotensin
receptor blocker; AF 5 atrial ﬁbrillation; AV 5 atrioventricular;
CRT5 cardiac resynchronization therapy; LBBB5 left bundle branch block;
LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart
Association; SD 5 standard deviation.aCRT patients received synchronized LV pacing 58.6% 6
33.9% of the time over the course of the study. The incidence
of the primary outcome (AF .48 hours) was 4.2% in aCRT
patients compared with 7.4% in convCRT (HR 5 0.60;
95% CI 5 0.19–1.85; P 5 .37). In contrast, in patients with
prolonged baseline AV conduction (in aCRT, LV-only pacing
is used only when the AV interval is,200ms), aCRT patients
received synchronized LV pacing 14.4%6 25.7% of the time.
The incidence of the primary outcome was 12.8% in aCRT pa-
tients compared with 27.4% in convCRT patients (HR5 0.45;
95% CI 5 0.24–0.85; P 5 .01).Additional outcomes
Subgroup analysis showed consistent effect favoring the aCRT
patients except for patients with LA area 18.5 mm2 or on
antiarrhythmic medication at baseline. As shown in Figure 2,
the HR point estimates favor aCRT; however, note conﬁdence
intervals overlapping with the line of no effect. No signiﬁcant
interaction effect was detected across subgroups.
AF episodes adjudicated as clinical adverse eventswere less
common with aCRT; 4.3% of patients in the aCRT compared
with 12.7% in the convCRT therapy arm (HR5 0.39; 95% CI
5 0.19–0.79; P 5 .01). We investigated additional measures
of AF. Table 3 shows that aCRT does not seem to affect short
duration AF, but it does affect longer duration episodes as evi-
denced by similar HRs from 1 full day to 30 consecutive days
or more. For example, 7.7% of patients with aCRT and 11.3%
of patients with convCRT had developed an episode of persis-
tent AF (.7 days) by the 24-month follow-up visit (HR 5
0.68; 95% CI5 0.19–1.03; P 5 .23).LA remodeling
Similar proportions of patients were LA responders; 70 of
256 (27.3%) of the aCRT group compared with 38 of 124
(30.7%) in the convCRT group (P 5 .50). In the
LA-responder patients, risk of AF was 82% lower with
aCRT beyond the 6-month follow-up visit (HR 5 0.18;
95% CI5 0.37–0.91; P5 .02). In patients with no observed
reverse remodeling, there was a trend for a reduced risk of AF
Table 2 Multivariable predictors of primary end point (episode of atrial ﬁbrillation .48 hours) using the Cox proportional hazards model
Variable Units/level Hazard ratio (95% CI) P value
Randomization Adaptive CRT 0.51 (0.29–0.91) .02
History of AF Yes 3.31 (1.76–6.24) .0002
Left atrial area Per 2 mm2 1.12 (1.03–1.22) .007
Age Per 10 y 1.62 (1.12–2.34) .01
QRS morphology LBBB 0.50 (0.26–0.95) .03
Etiology Ischemic 0.53 (0.29–1.00) .05
AV interval Normal AV 0.54 (0.26–1.09) .09
LVEF Per 5% 0.85 (0.67–1.07) .16
Antiarrhythmic On drug 1.45 (0.73–2.90) .29
QRS Per 10 ms 0.96 (0.84–1.10) .53
Race Nonwhite 0.91 (0.38–2.17) .84
Sex Female 0.97 (0.49–1.93) .94
AF 5 atrial ﬁbrillation; AV 5 atrioventricular; CI 5 conﬁdence interval; CRT 5 cardiac resynchronization therapy; LBBB 5 left bundle branch block.
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0.66; 95% CI 5 0.29–1.48; P 5 .30).Discussion
In this study, we found that patients who received an adaptive
therapy that continuously optimizes CRT experienced a 46%
reduced incidence of AF episodes lasting.48 hours at up to
2 years of follow-up. We found that most of the reduction in
AF occurred in subgroups with prolonged AV conduction at
baseline and in patients with signiﬁcant LA reverse remodel-0.01 0.1 1 10
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Figure 2 Incidence of primary end point in subgroups.ing. These data build on previously reported evidence of the
aCRT algorithm increasing responder rates and improving
clinical outcomes.22
Although many observational studies have suggested that
CRT reduces the risk of AF,11–16 data from 3 large clinical
trials have shown conﬂicting results. In the Cardiac
Resynchronization in Heart Failure (CARE-HF) trial, after
a mean follow-up period of 29 months, AF occurred in
16% of patients in the CRT group compared with 14% of
those who received medical therapy only (P 5 .79).17 There
was no difference in the time until ﬁrst onset of AF between
groups. Mortality was higher in patients who developed AF;
however, CRT improved the outcome regardless of whether
AF developed. It should be noted that AF was detected by
means of electrocardiography during scheduled and adverse
events and not from device diagnostics, and hence the inci-
dence of AF is likely underestimated.
In the Multicenter Automatic Deﬁbrillator Implantation
with Cardiac Resynchronization Therapy (MADIT-CRT)
trial, CRT-D and implantable cardioverter-deﬁbrillator
(ICD) patients showed similar 3-year cumulative probabili-
ties of device-detected atrial arrhythmias (7% vs 9%, respec-
tively; P 5 .63).18 However, if CRT led to LA remodeling,
deﬁned as .20% reduction in LA volume at 1 year post
implant, then there was a reduction in atrial arrhythmia
with CRT-D.
In the Resynchronization-Deﬁbrillation for Ambulatory
Heart Failure Trial (RAFT), electrocardiography-detected
or device-detected AF episodes (deﬁned as AF lasting 30
seconds) occurred in 45% of patients randomized to ICD
and 50% randomized to CRT-D.41 months.19 After adjust-
ing for competing risk of death, randomization to CRT-Dwas
associated with a 20% increased risk of AF (P 5 .045).19
Among those with 1 episode of device-detected AF, 16%
and 15% of patients subsequently developed persistent and
permanent AF forms, respectively, with no signiﬁcant
between-group differences.19
The explanation for the observed reduction in AF with
aCRT is likely multifactorial and is not fully understood.
We found that most of the reduction occurred in patients
with prolonged AV conduction at baseline. Patients who
Table 3 Incidence of atrial ﬁbrillation at 24 mo
Minimum AF duration
Incidence at 24 mo*
Hazard ratio P value†Adaptive CRT (n 5 312), % Conventional CRT (n 5 160), %
6 min in 1 d 35.8 38.9 0.98 .93
1 d of .23 h 10.9 18.1 0.60 .05
2 consecutive days of .23 h 8.7 16.2 0.54 .03
7 consecutive days of .23 h 7.7 11.3 0.68 .23
30 consecutive days of .23 h 5.3 8.7 0.53 .10
AF 5 atrial ﬁbrillation; CRT 5 cardiac resynchronization therapy.
*Kaplan–Meier estimate.
†AF rates compared by log-rank tests; AF burden categories compared by the Fisher exact test; and the mean AF burden compared by the Wilcoxon rank-sum test.
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14% of the time and biventricular pacing 81% of the time.
Thus, the major mechanism of beneﬁt is likely not due to a
reduction in RV pacing. In patients with prolonged AV inter-
val, the aCRT algorithm continuously assesses the patient’s
P-wave conduction interval, AV conduction, and QRS con-
duction interval, resulting in minute-to-minute dynamic ad-
justments to AV and VV pacing intervals. Thus, more
physiological AV intervals may in part explain the beneﬁt
of the algorithm. Note that the RAFT investigators postulated
that overly short programming of AV intervals may explain
their observation of increased AF with CRT.19 Additional
research should focus on elucidating the mechanism of
beneﬁt. Such research would have potential clinical rele-
vance to additional patient populations. Other device algo-
rithms for optimization of CRT have been described.29–31
To our knowledge, however, the current report is the ﬁrst
to describe a reduction in AF.
Another observation of our study was the relationship be-
tween LA remodeling (reduction in LA area) and AF. Similar
proportions of patients were LA responders at the 6-month
follow-up visit; 27% of the aCRT group compared with
31% of patients with convCRT. In the LA-responder patients,
risk of AF was 82% lower with aCRT beyond the 6-month
follow-up visit. In patients with no observed reverse remod-
eling, there was a nonsigniﬁcant trend for a reduced risk of
AF beyond the 6-month follow-up visit. These data are
similar to results from MADIT-CRT. In that study, if CRT
was associated with LA remodeling, then there was a reduc-
tion in atrial arrhythmia with CRT (3%) compared with that
in nonresponders to CRT (9%) and ICD-only patients (7%)
(P 5 .03).18 The relationship between LA remodeling and
lesser incidence in AF also likely explains our observation
that the Kaplan–Meier curves diverge at 12 months
(Figure 1).Limitations
The primary limitations of this study are that it is a post hoc
analysis with modest sample size, and the effect of aCRT on
AF should be investigated in a larger study. The AdaptRes-
ponse Clinical Trial is a prospective study of 3000 patients
randomized to aCRT or convCRT (NCT02205359); the inci-
dence of AF is a prespeciﬁed secondary end point in that trial.Conclusion
In conclusion, aCRT is a recently described algorithm for
synchronized LV pacing and continuous optimization of
CRT. In the current study, we found patients receiving
aCRT experienced a reduced risk of AF compared with
convCRT. We found that most of the reduction in AF
occurred in patients with prolonged AV conduction at base-
line and in patients with LA remodeling.Acknowledgments
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